LabCorp has entered into an agreement to expand sale of Mitomics' prostate core mitomic test (PCMT) throughout the US. Under the agreement, urologists will be able to order Mitomics' PCMT kit, through LabCorp's specialized laboratory ...
Tags: LabCorp, Mitomics'prostate core mitomic test, PCMT, PCMT kit
CIGNA & CMC Life Insurance, a joint venture between CIGNA and China Merchants Group, has introduced a new health insurance product to provide high quality health coverage in China. Dubbed Pearl Plan, the product further expands the ...
Tags: insurance, health insurance, insurance service, insurance product
MDxHealth and PLUS Diagnostics have reached an agreement to co-promote MDxHealth's ConfirmMDx for prostate cancer in the US. ConfirmMDx is a laboratory-developed test (LDT), which assists urologists with identifying men who may safely ...
Tags: prostate cancer assay, cancer assessment, clinical research
Medivation and Astellas Pharma have launched Xtandi (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Xtandi, an oral, once-daily androgen receptor inhibitor ...
US Department of Defense has granted a Congressionally Directed Medical Research Programs (CDMRP) grant to Aduro BioTech to complete the preclinical development of a new therapeutic cancer vaccine for prostate cancer. Aduro's cancer ...
Tags: Aduro, cancer vaccine platform, IND
Astellas Pharma's Gonax drug used in the treatment of prostate cancer, has been awarded marketing rights in Japan. Based on the positive results from phase I, II studies in Japan and phase III studies in abroad, Astellas has applied for ...
Astellas Pharma has introduced Gonax (Degarelix Acetate), a gonadotrophin-releasing hormone (GnRH)-receptor blocker, for subcutaneous injection to treat prostate cancer in Japan. Gonax is designed to inhibit the binding of GnRH, a hormone ...
Janssen Research and Development has received the Priority Review for the supplemental New Drug Application (sNDA) for ZYTIGA from US Food and Drug Administration (FDA). Zytiga (abiraterone acetate) is administered in combination with ...
Tags: sNDA, priority review, FDA
Accuray Incorporated has entered into a definitive agreement to buy a developer of medical imaging software systems, Morphormics, for $5.7m. Morphormics' medical imaging software systems automatically recognize and extract anatomical ...
Tags: Medical Imaging Software, medical imaging software systems
Astellas Pharma and Medivation have announced the submission of marketing authorization application (MAA) to the European Medicines Agency (EMA) for enzalutamide to treat metastatic castration-resistant prostate cancer in men who have ...
Tags: enzalutamide, metastatic castration-resistant prostate cancer
The US Food and Drug Administration (FDA) has granted premarket approval (PMA) to Beckman Coulter's simple, non-invasive Prostate Health Index (phi) blood test. The phi test, indicated for use in men with a prostate-specific antigen (PSA) ...
Tags: phi blood test, Prostate Health Index Test, immunoassay systems
Janssen Research & Development has announced that it has submitted a supplemental New Drug Application to FDA for ZYTIGA(abiraterone acetate). Janssen-Cilag International NV has also sent a type II variation to the European Medicines ...
Medivation and Astellas Pharma have announced the submission of new drug application (NDA) for enzalutamide (formerly MDV3100) to the FDA. The enzalutamide has been studied in patients with castration-resistant prostate cancer who ...
Tags: enzalutamide, new drug application, pharmaceutical product
Sanofi and Regeneron Pharmaceuticals have received FDA priority review for the biologics license application (BLA) of ZALTRAP (aflibercept) as a treatment for metastatic colorectal cancer (mCRC). The filing was based on the Phase III ...